Molecular resistance: An early indicator for treatment change?

Carmen Fava, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Vigilant monitoring of a patient's response to current treatment is imperative to the management of chronic myeloid leukemia (CML). Early identification of treatment failure may increase the probability that alternative therapy will be effective. This review discusses the use of molecular monitoring in the timely detection of failure of imatinib treatment. Changes in the levels of BCR-ABL transcripts are predictive of response or relapse. Patients achieving a major molecular response (MMR) within 12 months of treatment may experience longer cytogenetic remission. Accumulating evidence also suggests that lower transcript levels observed ≤ 6 months after the start of treatment are associated with improved patient outcomes. For patients with primary or secondary imatinib resistance (or intolerance), dasatinib or nilotinib may be prescribed. These agents have demonstrated activity in patients harboring imatinib-resistant BCR-ABL mutations, except for the T315I substitution.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalClinical Lymphoma, Myeloma and Leukemia
Volume12
Issue number2
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Treatment Failure
Physiologic Monitoring
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Complementary Therapies
Cytogenetics
Recurrence
Mutation
Imatinib Mesylate
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Dasatinib

Keywords

  • BCR-ABL inhibitor
  • Imatinib intolerance or resistance
  • Major molecular response
  • Monitoring response
  • Treatment failure

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Molecular resistance : An early indicator for treatment change? / Fava, Carmen; Kantarjian, Hagop; Cortes, Jorge.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 12, No. 2, 01.04.2012, p. 79-87.

Research output: Contribution to journalReview article

@article{26362e48ea4f4624bdb6384c4798b4bb,
title = "Molecular resistance: An early indicator for treatment change?",
abstract = "Vigilant monitoring of a patient's response to current treatment is imperative to the management of chronic myeloid leukemia (CML). Early identification of treatment failure may increase the probability that alternative therapy will be effective. This review discusses the use of molecular monitoring in the timely detection of failure of imatinib treatment. Changes in the levels of BCR-ABL transcripts are predictive of response or relapse. Patients achieving a major molecular response (MMR) within 12 months of treatment may experience longer cytogenetic remission. Accumulating evidence also suggests that lower transcript levels observed ≤ 6 months after the start of treatment are associated with improved patient outcomes. For patients with primary or secondary imatinib resistance (or intolerance), dasatinib or nilotinib may be prescribed. These agents have demonstrated activity in patients harboring imatinib-resistant BCR-ABL mutations, except for the T315I substitution.",
keywords = "BCR-ABL inhibitor, Imatinib intolerance or resistance, Major molecular response, Monitoring response, Treatment failure",
author = "Carmen Fava and Hagop Kantarjian and Jorge Cortes",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.clml.2011.12.004",
language = "English (US)",
volume = "12",
pages = "79--87",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Molecular resistance

T2 - An early indicator for treatment change?

AU - Fava, Carmen

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Vigilant monitoring of a patient's response to current treatment is imperative to the management of chronic myeloid leukemia (CML). Early identification of treatment failure may increase the probability that alternative therapy will be effective. This review discusses the use of molecular monitoring in the timely detection of failure of imatinib treatment. Changes in the levels of BCR-ABL transcripts are predictive of response or relapse. Patients achieving a major molecular response (MMR) within 12 months of treatment may experience longer cytogenetic remission. Accumulating evidence also suggests that lower transcript levels observed ≤ 6 months after the start of treatment are associated with improved patient outcomes. For patients with primary or secondary imatinib resistance (or intolerance), dasatinib or nilotinib may be prescribed. These agents have demonstrated activity in patients harboring imatinib-resistant BCR-ABL mutations, except for the T315I substitution.

AB - Vigilant monitoring of a patient's response to current treatment is imperative to the management of chronic myeloid leukemia (CML). Early identification of treatment failure may increase the probability that alternative therapy will be effective. This review discusses the use of molecular monitoring in the timely detection of failure of imatinib treatment. Changes in the levels of BCR-ABL transcripts are predictive of response or relapse. Patients achieving a major molecular response (MMR) within 12 months of treatment may experience longer cytogenetic remission. Accumulating evidence also suggests that lower transcript levels observed ≤ 6 months after the start of treatment are associated with improved patient outcomes. For patients with primary or secondary imatinib resistance (or intolerance), dasatinib or nilotinib may be prescribed. These agents have demonstrated activity in patients harboring imatinib-resistant BCR-ABL mutations, except for the T315I substitution.

KW - BCR-ABL inhibitor

KW - Imatinib intolerance or resistance

KW - Major molecular response

KW - Monitoring response

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=84858963632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858963632&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2011.12.004

DO - 10.1016/j.clml.2011.12.004

M3 - Review article

C2 - 22285607

AN - SCOPUS:84858963632

VL - 12

SP - 79

EP - 87

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -